Lecture : Although neoadjuvant chemotherapy has been investigated in the past in the management of localized pancreatic adenocarcinoma with the expectation that it may lead to downstaging, no practice-changing data were ever generated, mainly because of low response rates to conventional chemotherapeutic regimens. In recent years, however, the emergence of more effective chemotherapy such as FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel has renewed interest in the use of neoadjuvant chemotherapy in localized pancreatic adenocarcinoma. In terms of radiotherapy, novel types of radiotherapy such as stereotactic body radiotherapy also may enhance the outcomes of these patients. Because there is no randomized trial to compare the different chemotherapy regimens and therapeutic modalities, there is no globally established single protocol for the neoadjuvant therapy in localized pancreatic adenocarcinoma. In this session, recent update and current trends of neoadjuvant therapy for localized pancreatic adenocarcinoma will be presented.